The Gynecologic Oncology Group (GOG) is the foremost multidisciplinary cooperative clinical trial research group devoted to the study of gynecologic malignancies. Since its inception in 1970, the GOG has been a recognized leader in the development of new forms of treatment and has relied on Phase III trials as the design to identity new standards of care for cancers of the female genital tract, in particular ovarian carcinoma, carcinoma of the uterine cervix, and endometrial carcinoma. Supporting that major activity are the concerted efforts of special studies committees focusing on translational research, developmental therapeutics, quality of life, and cancer prevention and control;and modality committees providing recent approaches and procedures in each of the relevant diagnostic and therapeutic disciplines. The GOG has an active, effective program in the study of new surgical and radiation approaches as well as new systemic agents. In patients with advanced ovarian cancers, GOG studies have defined the current standard of care of cytoreductlve surgery followed by systemic therapy including a taxane and a platinum compound. Current studies seek to improve on this standard with trials of intraperitoneal therapy, targeted agents, and maintenance therapy for those in complete remission. In patients with carcinoma of the cervix, GOG studies have identified new chemotherapeutic agents and combinations for use in the setting of advanced or recurrent disease and have set the standard of care for earlier stage cervix cancer (FIGO stages IB-IVA) as concurrent, cisplatin-based chemoradiation. Current and planned investigations will explore better chemoradiation combinations and the role of targeted agents such as bevacizumab. In patients with endometrial carcinoma, GOG studies have changed the paradigm for the management of advanced or recurrent disease by defining roles for chemotherapy in this difficult patient population. The GOG also has an active effort in less common gynecologic malignancies including uterine sarcomas, gestational trophoblastic disease, germ cell tumors of the ovary, vulvar cancer, among others. Making all of this effort to improve the standard of care possible is an active and extensive effort to identity new approaches through developmental therapeutics and to develop a better understanding of the biology of these malignancies through an active and extensive translational research program. After more than 39 years, the GOG continues to be foremost in developing new strategies for managing these cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA027469-31S2
Application #
8401217
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1980-05-01
Project End
2016-03-31
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
31
Fiscal Year
2012
Total Cost
$109,000
Indirect Cost
$9,000
Name
Gynecologic Oncology Group
Department
Type
DUNS #
136664096
City
Crofton
State
MD
Country
United States
Zip Code
21114
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2017) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res :
McCourt, Carolyn K; Deng, Wei; Dizon, Don S et al. (2017) A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:101-106
Atri, Mostafa; Zhang, Zheng; Dehdashti, Farrokh et al. (2017) Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology 283:450-459
Rungruang, Bunja J; Miller, Austin; Krivak, Thomas C et al. (2017) What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer 123:985-993
Coleman, Robert L; Brady, Mark F; Herzog, Thomas J et al. (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779-791
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2017) Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer 27:730-737
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Rader, Janet S; Sill, Michael W; Beumer, Jan H et al. (2017) A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:291-297
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778

Showing the most recent 10 out of 508 publications